Two-Drug HIV Regimen Gains FDA Approval - Takeaway - MDSpire
FDA & Government News

Two-Drug HIV Regimen Gains FDA Approval

Phase 3 trials showed noninferior viral suppression vs standard three-drug therapy with similar safety outcomes

Share

  • 1

    FDA approved DOR/ISL for virologically suppressed HIV-

  • 2

    Once-daily regimen.

  • 3

    Similar viral suppression rates to standard antiretroviral therapy.

  • 4

    Maintained efficacy and safety through 96 weeks.

  • 5

    Tenofovir-free alternative for simplified treatment options.

  • 6

    Contraindications with strong CYP3A inducers.

  • 7

    Islatravir inhibits viral replication via reverse transcriptase interference.

Original Source(s)

Two-Drug HIV Regimen Gains FDA Approval

  • by Kathryn Wighton

  • April 21, 2026

Related Content

Varicella Pneumonia Requires IV Acyclovir

Case highlights need for early intravenous antiviral treatment in adults with rash and hypoxia

A Reliable Cold Chain is a Health Equity Issue

Why temperature-controlled logistics is a critical but overlooked foundation of equitable access to medicines

Are Respiratory Deaths Underreported?

Postmortem testing reveals gaps in respiratory virus diagnosis

  • April 21, 2026

  • 3 min